Back to top
more

Mersana Therapeutics (MRSN)

(Delayed Data from NSDQ)

$3.16 USD

3.16
1,210,152

+0.22 (7.48%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $3.15 -0.01 (-0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MRSN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Mersana Therapeutics, Inc. [MRSN]

Reports for Purchase

Showing records 121 - 140 ( 197 total )

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 121

03/30/2020

Daily Note

Pages: 94

Market Shudders But We See Names to Outperform.

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 122

03/28/2020

Industry Report

Pages: 12

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 123

03/24/2020

Daily Note

Pages: 5

MRSN Still a Go Even if SGO a No-Go

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 124

03/20/2020

Industry Report

Pages: 12

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 125

03/10/2020

Company Report

Pages: 11

Key Takeaways From KOL Dinner: XMT-1536 Has the Makings of a Compelling ADC

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 126

03/02/2020

Company Report

Pages: 5

4Q19 Financials; XMT-1536 Data at SGO Next

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 127

03/02/2020

Daily Note

Pages: 15

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 128

03/02/2020

Industry Report

Pages: 7

From TINA to Cash Is King and Other Musings

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 129

03/02/2020

Company Report

Pages: 9

Updating SGO Expectations Post FY19 Corporate Update; Target to $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 130

02/18/2020

Daily Note

Pages: 5

SGO a Go for Additional ''1536 Data, More to Come Later in 2020

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 131

02/18/2020

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 132

02/14/2020

Industry Report

Pages: 7

Runners up Is the New Killing It, and Other Tidbits

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 133

02/11/2020

Company Report

Pages: 9

Expectations for XMT-1536 at the SGO on March 30, 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 134

02/07/2020

Daily Note

Pages: 9

LetÂ’s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 135

01/21/2020

Company Report

Pages: 9

Expected Data Flow, and Available Activity and Safety Profile Bode Well for XMT-1536; Raising Target to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 136

01/10/2020

Company Report

Pages: 5

Continues to Escalate

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 137

01/10/2020

Daily Note

Pages: 4

Onward and Upward; Escalation/Expansion Panning Favorably, Clarification on Activity Could Revitalize This ADC Pureplay

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 138

01/09/2020

Daily Note

Pages: 18

2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 139

11/07/2019

Company Report

Pages: 9

So Far so Good on the Safety Front; Awaiting Activity Roll Out During 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 140

11/07/2019

Daily Note

Pages: 13

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party